Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylstilbestrol Diphosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.53 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.96 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylstilbestrol Diphosphate SCHEMBL2496868 | 1.00 | BLM (0.96) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL9370 | 0.98 | BLM (1.00) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL6231203 | 0.98 | BLM (1.00) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL3664191 | 0.95 | BLM (0.93) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL7617243 | 0.91 | BLM (0.87) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| SCHEMBL707840 | 0.91 | BLM (0.87) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| SCHEMBL707841 | 0.91 | BLM (0.87) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| SCHEMBL14608595 | 0.89 | BLM (0.81) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL5488347 | 0.88 | BLM (0.74) | BLMNR1I2SMN1; SMN2ESR1KMT2A | |
| Diethylstilbestrol Diphosphate SCHEMBL8937910 | 0.83 | BLM (0.72) | BLMNR1I2SMN1; SMN2ESR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138164-A1 | UNWANTED PHARMACEUTICAL FORMULATION DISPOSAL SYSTEM AND MAILER | VERDE ENVIRONMENTAL TECH INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12544813-B2 | Unwanted pharmaceutical formulation disposal system and mailer | VERDE ENVIRONMENTAL TECHNOLOGIES, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250050392-A1 | UNWANTED PHARMACEUTICAL FORMULATION DISPOSAL SYSTEM AND MAILER | VERDE ENVIRONMENTAL TECHNOLOGIES, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20240325609-A1 | POLYPEPTIDE MONOLITHS | TRUSTEES OF TUFTS COLLEGE | 2024-10-03 | — | — | US | disclosed |
| US-11883865-B2 | Blister pack disposal system | VERDE ENVIRONMENTAL TECHNOLOGIES, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230405650-A1 | UNWANTED PHARMACEUTICAL FORMULATION DISPOSAL SYSTEM | VERDE ENVIRONMENTAL TECHNOLOGIES, INC. (US) | 2023-12-21 | — | — | US | disclosed |
| US-20220314287-A1 | Blister Pack Disposal System | VERDE ENVIRONMENTAL TECHNOLOGIES, INC. | 2022-10-06 | — | — | US | disclosed |
| US-11389844-B2 | Blister pack disposal system | VERDE ENVIRONMENTAL TECHNOLOGIES, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3768220-A1 | BLISTER PACK DISPOSAL SYSTEM | Verde Environmental Technologies, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| EP-1836101-A2 | NON-TEARABLE CHILD RESISTANT BLISTER PACKAGE | CIMA LABS INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20060283760-A1 | Child resistant tablet package | CIMA LABS INC. (US) | 2006-12-21 | — | — | US | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
| US-20060283759-A1 | Bend and peel tablet package | CIMA LABS INC. | 2006-12-21 | — | — | US | disclosed |
| US-20060278558-A1 | Non-tearable child resistant blister package | CIMA LABS INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006076552-A2 | NON-TEARABLE CHILD RESISTANT BLISTER PACKAGE | CIMA LABS INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006076553-A2 | BEND AND PEEL TABLET PACKAGE | CIMA LABS INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006076705-A2 | CHILD RESISTANT TABLET PACKAGE | CIMA LABS INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-6645983-B1 | Heterocyclic imines such as 3-(4-methoxyphenyl)-1,4-dihydro-4 -quinolinone, used as anticarcinogenic agents having cytolysis efficiency; side effect reduction | LABORATOIRE L. LAFON (FR) | 2003-11-11 | — | — | US | disclosed |
| US-6593342-B1 | Activity on the proliferation of clonogenic cells in tumours and comprising an efficient amount of a compound selected among the compounds | LABORATOIRE L. LAFON (FR) | 2003-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138164-A1 | UNWANTED PHARMACEUTICAL FORMULATION DISPOSAL SYSTEM AND MAILER | PDE12, PDE2A, PLEC | ESR1 1631/4885ESR2 3158/4885BLM 2429/4885 |
| US-12544813-B2 | Unwanted pharmaceutical formulation disposal system and mailer | PDE12, PLEC, PTPRS | ESR1 2207/4885ESR2 3461/4885BLM 2975/4885 |
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | KLK3, ACP3, NR5A1 | ESR1 454/4885ESR2 223/4885BLM 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.